Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. (Q53050556)

10 May 2018

title

Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. (English)

1 reference

10 May 2018

0 references

0 references

Kevin A DaSilva

1

1 reference

10 May 2018

Mary E Brown

series ordinal

2

1 reference

10 May 2018

JoAnne McLaurin

series ordinal

3

1 reference

10 May 2018

language of work or name

English

0 references

publication date

14 January 2009

1 reference

10 May 2018

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

10 May 2018

volume

27

1 reference

10 May 2018

issue

9

1 reference

10 May 2018

page(s)

1365-1376

1 reference

10 May 2018

gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

DNA vaccination: the answer to stable, protective T-cell memory?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

DNA vaccines: a key for inducing long-term cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Immunomodulation by apoptosis-inducing caspases for an influenza DNA vaccine delivered by gene gun.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Prodomain-dependent nuclear localization of the caspase-2 (Nedd2) precursor. A novel function for a caspase prodomain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Conversion of procaspase-3 to an autoactivating caspase by fusion to the caspase-2 prodomain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Lymphokine control of in vivo immunoglobulin isotype selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Will anti-amyloid therapies work for Alzheimer's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.044

10.1016/J.VACCINE.2008.12.044

7 January 2021

Identifiers

DOI

1 reference

10 May 2018

PubMed ID

19150380

1 reference

10 May 2018